U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Approval Year

2015
472
Name Type Language
TALIMOGENE LAHERPAREPVEC
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
talimogene laherparepvec [INN]
Preferred Name English
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE
Common Name English
TALIMOGENE LAHERPAREPVEC [USAN]
Common Name English
IMLYGIC
Brand Name English
ONCOVEXGM-CSF
Common Name English
Talimogene laherparepvec [WHO-DD]
Common Name English
JS1 34.5-HGMCSF 47- PA-
Code English
JS-1 34.5-HGMCSF
Code English
TALMIMOGENE LAHERPAREPVEC
Common Name English
ONCOVEX
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C2139
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
WHO-ATC L01XX51
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
NCI_THESAURUS C717
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
FDA ORPHAN DRUG 334011
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
EMA ASSESSMENT REPORTS IMLYGIC (AUTHORIZED: MELANOMA)
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
NCI_THESAURUS C1962
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
Code System Code Type Description
WIKIPEDIA
Talimogene laherparepvec
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY
DRUG CENTRAL
5180
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY
RXCUI
1721264
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY RxNorm
NCI_THESAURUS
C61314
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY
FDA UNII
07730V90L6
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY
SMS_ID
100000158328
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY
CAS
1187560-31-1
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY
ChEMBL
CHEMBL2108727
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY
DRUG BANK
DB13896
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY
DAILYMED
07730V90L6
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY
USAN
XX-66
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY
INN
9402
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY
EVMPD
SUB168372
Created by admin on Wed Apr 02 08:03:50 GMT 2025 , Edited by admin on Wed Apr 02 08:03:50 GMT 2025
PRIMARY
Sugar Site Range Site Count
Deoxyribose (DNA) 1_1-1_7556 7556 / 7556
Linkage Site Range Site Count
Phosphate 1_1-1_7556 7556 / 7555
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966